
What lies ahead for the Glomerulonephritis market?
Ongoing clinical trial activities drive market growth.
The Glomerulonephritis market is expected to surge by 2034, amidst the rising demand for targeted therapies, according to DelveInsight.
“Key options include immunosuppressive drugs, investigational targeted therapies, and supportive measures such as ACE inhibitors or ARBs,” the report said.
In addition, ongoing clinical trial activities and the launch of emerging therapies are expected to further drive market growth.
The sector’s expansion is attributed to the rising prevalence of chronic kidney diseases and improved diagnostic capabilities.